{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-020595","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2023-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.188389+00:00","generated_at":"2026-06-14T05:07:51.375265+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vivos Q1 revenue up 6% to $3.9M; operating expenses cut 20%; net loss narrows","bullets":["Revenue $3.9M (+6% YoY); gross margin 61% vs 70% on higher VIP training costs.","Operating expenses fell 20%; net loss reduced with $3.2M non-cash derivative gain.","VIP enrollments 38 (+19% YoY); VIP revenue $1.3M (+42%). Cash $7.0M.","Acquired AFD patents/TMD-Bruxism products; POD study showed 92% migraine resolution.","Targeting positive cash flow in Q1 2024; multiple DSO/DME pilots underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-020595","json":"https://secwatch.observer/filing/0001493152-23-020595.json","markdown":"https://secwatch.observer/filing/0001493152-23-020595.md","text":"https://secwatch.observer/filing/0001493152-23-020595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223020595/0001493152-23-020595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223020595/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:07:51.375265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"886f0275a4c8268b48b546a847d1beb0919ce2cf","claim":"Vivos Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $3.9 million.","evidence_excerpt":"Revenue was $3.9 million for the first quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223020595/0001493152-23-020595-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$3.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}